Record ID: MS-N081 · Family: Nutrition and dietary patterns / survivorship · Clinical question: Is eating nuts after treatment associated with recurrence or survival in stage III colon cancer?
Evidence label: Favorable prospective observational association; nut intake was not randomized, so causation is not established.
Evidence at a glance
- Benefit: Two or more one-ounce servings weekly were associated with better disease-free and overall survival.
- Certainty: Low for a causal cancer-control effect despite prospective collection and adjustment.
- Risk: Allergy, choking risk, excess calories in some contexts and interactions with symptom-specific diets.
- Cancer control: Association only; this does not show that nuts treat residual cancer.
What was studied
Within the CALGB 89803 adjuvant-chemotherapy trial, 826 eligible people with stage III colon cancer completed food-frequency questionnaires during and after chemotherapy. The chemotherapy was randomized; nut consumption was self-selected.
Researchers compared people reporting at least two one-ounce servings of nuts per week with people reporting none. Median follow-up was 6.5 years.
What the results show
At least two servings per week was associated with disease-free survival HR 0.58 (95% CI 0.37–0.92; trend P=0.03) and overall survival HR 0.43 (95% CI 0.25–0.74; trend P=0.01). Subgroup analyses suggested the association was mainly with tree nuts.
These are relative associations. The analysis cannot determine whether nuts caused the difference or instead marked broader diet, activity, metabolic health or socioeconomic patterns.
Important limits
- Diet was self-reported and not randomized.
- Residual confounding and reverse causation remain possible.
- This cohort also underlies several other dietary analyses; those reports are not independent trials.
- The highest-intake group was relatively small, widening uncertainty.
- The findings do not define an optimal type, dose or preparation of nuts.
Safety and practical context
Tree-nut or peanut allergy can be severe. After bowel surgery, with obstruction risk, poor dentition or swallowing difficulty, texture and portion should be discussed with the care team.
Questions for the care team
- Is this observational association relevant to my stage and treatment?
- Do allergy, bowel symptoms, calorie needs or swallowing issues change the advice?
- Would a broader dietary pattern matter more than one food?
- How can I avoid interpreting relative risk as a guaranteed personal benefit?
Sources checked
Funding and conflicts: The analysis was embedded in a National Cancer Institute cooperative-group trial; consult the paper for the complete grant and author-disclosure list.
Last literature search: October 20, 2026 · Record appraisal: October 20, 2026
Educational information only. This record is not a prescription and does not replace advice from the oncology team, registered dietitian or oncology pharmacist.
